Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Equipment >

Titan Medical Inc. (TITXF)

Add TITXF Price Alert      Hide Sticky   Hide Intro
Moderator: dndodd, glg20, drrc1949, investinthefuture, cptjsd, SurgicalTechnologist
Search This Board: 
Last Post: 6/24/2017 3:58:47 PM - Followers: 264 - Board type: Free - Posts Today: 11

This One Filing Means TITAN MEDICAL INC  (OTCMKTS:TITXF) Just Became More Attractive

Titan Medical Inc. Announces Pricing of Marketed Offering of Units

Mr. Martin Bernholtz, Chairman of the Board, is pleased to advise that the entire Board of Directors and Officers of the Company have committed to participate in this offering.

TORONTO, ON–(Marketwired – June 20, 2017) –

Titan Medical Inc. (“Titan” or the “Company“) (TSX: TMD) (OTCQB: TITXF) is pleased to announce today that it has priced its previously announced marketed offering (the “Offering“) of units of the Company (the “Units“). Pursuant to the Offering, Titan will issue Units at a price of CDN $0.15 per Unit (approximately US $0.11 per Unit). Each Unit is comprised of one common share of the Company (a “Common Share“) and one Common Share purchase warrant of the Company (a ” Warrant“). Each Warrant is exercisable for one Common Share at a price of CDN $0.20 (approximately US $0.15), for a period of five years following the closing of the Offering (the “Closing“).


Titan Medical Named Best Canadian IP Department at 2017 International Legal Alliance Summit & Awards

Director of Strategic Development and Intellectual Property Jasminder Brar recognized as a global IP strategy leader by Intellectual Asset Management

TORONTO, ON--(Marketwired - June 19, 2017) - Titan Medical Inc. ("Titan" or the "Company") (TSX: TMD) (OTCQB: TITXF), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (MIS), was named "Best Canadian IP Department" at the International Legal Alliance Summit & Awards (ILASA) event held on June 15, 2017 in New York City. The event was organized by the Paris-based Leaders League and gathered more than 450 senior representatives from leading law firms as well as general counsel from more than 40 countries. Winners were chosen by specialized jury panels and the full list is available here

Separately, Intellectual Asset Management (IAM) named Jasminder Brar, Titan Medical's Director of Strategic Development and Intellectual Property, to the 2017 edition of IAM Strategy 300 - The World's Leading IP Strategists. The guide lists the individuals that in-depth research undertaken by a team based in London, Washington, DC and Hong Kong has shown possess world-class skills in the development and rollout of strategies that maximize the value of patents, copyright, trademarks and other IP rights. This is the third consecutive year that Mr. Brar has been included in the guide. The 2017 edition can be found here.

"Intellectual property is vital to our success and we are thrilled that our efforts and accomplishments have been recognized by our peers," said David McNally, President and CEO of Titan Medical. "ILASA is a prestigious annual event and we are honored to share the award for Best Canadian IP Department with Bombardier Aerospace, a giant Canadian innovator." 

"I also want to congratulate Jasminder on his inclusion in IAM Strategy 300 for the third consecutive year and acknowledge his leadership and know-how in advancing our intellectual property efforts."

SPORT™ Surgical System

A robotic system like no other!

The SPORT Surgical System is a versatile single incision advanced robotic surgical system that features state-of the-art multi-articulated instruments with single-use replaceable tips, 3D high definition visualization on a flat-screen monitor, ergonomic open workstation and a single-arm mobile patient cart for ease of set up while enabling broad applications of single and multi-quadrant surgeries previously not possible with current robotic solutions.

Titan Medical Inc. is a Canadian public company, headquartered in Toronto, Ontario, that trades on the Toronto Stock Exchange (TMD) and the OTCQX in the United States (TITXF). Titan is developing the SPORT™ (Single Port Orifice Robotic Technology) Surgical System for use in minimally invasive surgery (“MIS”) that is expected to be commercially available in 2019. Titan’s robotic surgical system is being designed to expand robotic surgery into areas that are currently underserviced. This will allow surgeons to perform procedures within small to medium size surgical spaces such as general surgery and cholecystectomy. Currently, the most common medical procedures for which robotic systems are used are hysterectomies and prostatectomies. Titan plans to expand the scope and obtain approval for various surgical procedures as outlined in their Corporate Presentation.

The SPORT™ Surgical System includes the following:
* a single-port surgeon controlled robotic platform that includes a 3D vision system and interactive instruments for performing MIS procedures, and

* a surgeon workstation that provides the surgeon with an interface to the robotic platform   for controlling the interactive instruments and providing a 3D endoscopic view of inside a patient’s body during MIS procedures.


David J. McNally, Chief Executive Officer, Director


Mr. McNally joins Titan after serving as the founder, President, CEO and Chairman of the Board of Domain Surgical Inc., founded in 2009, Domain is based in Salt Lake City, Utah. Mr. McNally brings substantial experience in areas of extraordinary leadership skills with all facets of building innovative medical device companies including clinically-focused product design and development, capital formation, regulatory clearance, and commercialization. Mr. McNally earned an MBA from the University of Utah, holds a Bachelor of Science degree in Mechanical Engineering from Lafayette College, Easton, PA and is the co-inventor of more than 30 U.S. and international patents associated with ferromagnetic surgical devices and systems, electromagnetic and ultrasonic sensors, and medical fluid delivery systems


                                                                                  Surgeon Advisory Board

Arnold Advincula, MD

Dr. Advincula is Vice-Chair of Women’s Health & Chief of Gynecology at the Sloane Hospital for Women, Columbia University Medical Center/New York Presbyterian Hospital. Formerly, he was Professor of Obstetrics and Gynecology, Director of the Minimally Invasive Surgery Division and Fellowship, and Director of the Endometriosis Center at the University of Michigan. More recently, he was Director of the Center for Specialized Gynecology and Director of the Education Institute at the Nicholson Center, an advanced medical and surgical simulation training facility at Florida Health. He is currently Vice President of the American Association of Gynecologic Laparoscopy and a Member-at-Large for the Society of Gynecologic Surgeons. He is a leader in minimally invasive surgical techniques and one of the world’s most experienced gynecologic robotic surgeons, who has published and taught extensively in the area of minimally invasive surgery, as well as developed surgical instruments that are in use worldwide.

Juliane Bingener-Casey, MD

Dr. Juliane Bingener is Professor of Surgery, Mayo Clinic College of Medicine, and Vice Chair for Quality, Safety and Service in the Mayo Clinic Department of Surgery. She has a joint appointment in the Division of Gastroenterology and Hepatology, which supports her clinical interests in minimally invasive surgery, endoscopy, and gastrointestinal disease. Her research focuses on patient reported outcomes and novel technology in the diagnosis and treatment of these diseases. Dr. Bingener’s previous work included the development of a Natural Orifice Translumenal Endoscopic Surgery (NOTES) technique for using an omental patch to close perforated ulcers. Her ongoing interests focus on the development, study, and implementation of innovative endoscopic and laparoscopic approaches for gastrointestinal diseases.

W. Douglas Boyd, MD

Dr. Boyd is a Professor of Surgery and Director of Robotics and Biosurgery at the University of California Davis. He is Head of Adult Cardiac Surgery and Surgical Director of the Transcatheter Valve Program. He is recognized for his pioneering work in cardiothoracic surgery and for his use of robotic-assisted surgical systems. He specializes in minimally invasive cardiac and robotic-assisted heart surgery. Dr. Boyd completed the world’s first closed-chest, beating-heart coronary artery bypass surgery using a robotic system in 1999. Prior to his appointment as a professor of surgery at UC Davis Health System, Dr. Boyd served as chair of the Department of Cardiothoracic Surgery at the Cleveland Clinic in Florida. As the author of more than 70 peer-reviewed, journal articles, Dr. Boyd’s research interests include cardiac tissue regeneration using extracellular matrix/stem cells, new techniques for robot-assisted minimally invasive coronary artery revascularization, valve surgery and tele-surgery. He is a graduate of Carleton University in Ottawa, Canada and obtained his medical degree from the University of Ottawa, Canada.

Demetrius EM Litwin, MD, MBA, FRCS, FACS, FICS

Dr. Litwin trained in General Surgery at the University of Saskatchewan, and completed a hepatobiliary fellowship at the University of Toronto. He was an early pioneer in laparoscopic surgery, having performed the first laparoscopic cholecystectomy in Western Canada in 1990 and the first laparoscopic colectomy in Canada in 1991. He was a leader in educating a large number of surgeons across Canada in basic and advanced laparoscopic techniques. During the early advent of minimally invasive surgery, he innovated new laparoscopic approaches to the spine and aorta, and he participated in the development of HandPortTM, a hand assist device for laparoscopic surgery. In 1993, Dr. Litwin became the Director of Minimally Invasive Surgery at the University of Toronto. In 1997, he moved to the University of Massachusetts as Chief of Minimally Invasive Surgery. Since 2004, he has been Chairman of Surgery at the University of Massachusetts Medical School and UMass Memorial Medical Center, one of the largest Academic Health Sciences Centers in Massachusetts. There, he continues to practice minimally invasive surgery of the abdomen in addition to his administrative role.

Lee L Swanstrom, MD, FACS

Dr. Swanstrom heads the Division of GI and Minimally Invasive Surgery at the Oregon Clinic and is Director of the Providence Health System’s Complex GI and Foregut Surgery Postgraduate Fellowship Program. In addition, he is Clinical Professor in the Department of Surgery at OHSU, a Director of the American Board of Surgery, and Past President of both the Society of American Gastrointestinal Endoscopic Surgeons (SAGES) and the Fellowship Council (FC). Most recently, he became the Chief Innovations Officer and Director of the Innovations Fellowship at the Institutes des Hôpitalo Universitaires of the University of Strasbourg, France. He is the editor of Surgical Innovation and the author of over 300 scientific papers and 50 book chapters. This has resulted in 13 patents and a successful medical device startup company. He is and has been an investigator on numerous outcomes research studies for new procedures such as Natural Orifice Translumenal Endoscopic Surgery (NOTES) to determine their safety and efficacy for establishing new standards of care. He remains focused on developing innovative approaches to the minimally invasive treatment of foregut and other gastrointestinal disorders.

John Valvo, MD

Dr. Valvo, a practicing surgeon, is the Executive Director of Robotic and Minimally Invasive Surgery at Rochester General Hospital in Rochester, New York, where he formerly was the Chief of Urology. Following a 20-year career performing open surgery, Dr. Valvo founded the robotic surgery program at Rochester General Hospital in early 2004, which currently ranks in the top two percent of robotic surgery volume in the United States. The program has trained over 30 robotic surgeons and enabled the completion of more than 7,000 robotic urology, gynecology, general and colorectal surgeries to date. Dr. Valvo has authored more than 100 scientific articles and helped start many robotic programs in the northeast. His focus on robotic surgery credentialing led to a notable published paper on policy guidelines for robotic surgery. He is a fellow of the American College of Surgeons and American Urological Association, and a member of the Society for Laparoscopic Surgeons. 






  Patent #                                                    Title of Invention
1 8,930,027   Force Feedback System
2 8,792,688   Methods, systems and devices for three dimensional input and control methods and systems based thereon
3 8,768,509   Snaking robotic arm with movable shapers
4 8,347,754   Multi articulating robotic instrument
5 8,332,072   Robotic hand controller
6 8,306,656   Method and system for performing medical procedure
7 8,224,485   Snaking robotic arm with movable shapers
8 5,853,394   Catheter
9 5,607,407   Catheter assembly
10 4,785,868   Medical needle and method for making
  PUB. APP. NO.  Title

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#55897  Sticky Note Titan mentioned as a rebound play... jetuomi 06/21/17 09:45:29 PM
#40949  Sticky Note Titan Medical Gurufocus correct link nla 07/19/16 11:52:04 AM
#34285  Sticky Note Titan Medical Facebook Group SurgicalTechnologist 03/19/16 10:14:24 AM
#56022   I read it twice and don't see a Adrock 06/24/17 03:58:47 PM
#56021   Excellent find, Fly!!!! I am so pissed I Longmoney 06/24/17 03:57:43 PM
#56020   Great find!! Looks like those Titan-Patel-Verb connections are SurgicalTechnologist 06/24/17 02:43:51 PM
#56019   With this offering the door is wide open SurgicalTechnologist 06/24/17 02:41:04 PM
#56018   So I assume this hints at Titan being DRG1025 06/24/17 01:57:35 PM
#56017   Giddyup. Times Yours 06/24/17 01:02:54 PM
#56016   See this And the very ne flybabyfly 06/24/17 12:57:46 PM
#56015   Amazing!! jetuomi 06/24/17 12:11:26 PM
#56014   According to their SEDAR filings they have completed SurgicalTechnologist 06/24/17 07:46:48 AM
#56013   Who knows why we're not mentioned. I don't SurgicalTechnologist 06/24/17 06:58:12 AM
#56012   Welcome to the club. How confident are we cptjsd 06/24/17 02:00:09 AM
#56011   Why do you need to be told what CUIN2 06/23/17 11:53:41 PM
#56010   Should we all sell first thing Monday because gomer13 06/23/17 11:45:16 PM
#56009   All I got is f f f f pontiacg6 06/23/17 11:05:37 PM
#56008   Not even showing up in the mix CUIN2 06/23/17 10:48:36 PM
#56007   Why not this for us: "A rights scalpel 06/23/17 10:26:50 PM
#56006   There needs to be a a Katalyst to Katalyst89 06/23/17 09:25:42 PM
#56005   Heres a thought! STOP USING CAPS !!!! posilock 06/23/17 09:18:43 PM
#56004   PER THE SEDAR POSTED ON JUNE 21....AFTER THE suckitup 06/23/17 06:55:41 PM
#56003   Fda approval bet kids tuition 06/23/17 06:45:19 PM
#56002   I think we hear about initial design freeze. scalpel 06/23/17 05:40:12 PM
#56001   Last week of June coming up. What do DRG1025 06/23/17 05:20:51 PM
#56000   That interesting... maybe this is a dead giveaway BBS4 06/23/17 04:20:14 PM
#55999   If you have to ask...... RockoTaco 06/23/17 03:25:16 PM
#55998   Titan not mentioned as a competitor to the SurgicalTechnologist 06/23/17 03:15:31 PM
#55997   Lol itsallgood11 06/23/17 02:39:06 PM
#55996   When I wrote to Mr. Rosen requesting participation scalpel 06/23/17 02:35:47 PM
#55995   I think they should only need to know Times Yours 06/23/17 02:27:53 PM
#55994   In the US the offering is a regulation SurgicalTechnologist 06/23/17 02:07:37 PM
#55993   It's a Canadian company. They are only offering scalpel 06/23/17 02:05:16 PM
#55992   I don't know if I am correct but NoTshirt 06/23/17 02:02:20 PM
#55991   This for me has been the biggest pump pontiacg6 06/23/17 01:47:40 PM
#55990   Got mine down to .52/share. Couldn't be happier DRG1025 06/23/17 01:22:43 PM
#55989   Just averaged down to .33. JHOGG 06/23/17 01:16:49 PM
#55988   Hey, glad I caught you. While you're Times Yours 06/23/17 12:46:37 PM
#55987   Let's pray for that ! We Honeycomb777 06/23/17 12:40:04 PM
#55986   maybe he will stick around as long as you. RockoTaco 06/23/17 12:37:50 PM
#55985   Will VIP stick around as long as Fowler, Honeycomb777 06/23/17 12:23:43 PM
#55983   Just bought another 50,000 shares. I feel now DRG1025 06/23/17 12:21:00 PM
#55982   I find it perplexing and perhaps I've just Brave11 06/23/17 12:19:52 PM
#55981 RockoTaco 06/23/17 11:41:46 AM
#55980   Exactly how these MM's operate is still perplexing SurgicalTechnologist 06/23/17 11:40:09 AM
#55979   I just bought another 50k ORrep8 06/23/17 10:51:41 AM
#55978   I bought another 15k shares bc of positivity. Kswiss12 06/23/17 10:45:07 AM
#55977   Thanks TY. I really believe we get there SurgicalTechnologist 06/23/17 10:14:27 AM
#55976   No kidding. For the record, I Times Yours 06/23/17 10:07:55 AM
#55975   we need people buying as much as the glg20 06/23/17 10:07:15 AM
#55974   Your right not a good week to gauge SurgicalTechnologist 06/23/17 10:04:47 AM
#55973   Agree, too much happening to draw any conclusions hubwolf1 06/23/17 10:01:20 AM
#55972   Honestly, I had a good week, with less 66Mustang 06/23/17 09:51:26 AM